Real-world data confirmed the findings of JAVELIN Renal 101, supporting the combination of avelumab and axitinib in advanced renal cell carcinoma (RCC), said Axel Merseburger, MD, University Hospital Schleswig Holstein, Campus Lübeck, in Germany.
A real-world analysis of avelumab and axitinib to treat advanced renal cell carcinoma supports the frontline use of the combination and confirmed the findings of JAVELIN Renal 101 (NCT02684006), said Axel Merseburger, MD, professor of urology and chairman of the Department of Urology, University Hospital Schleswig Holstein, Campus Lübeck, and director of the Urologic Oncology Program, Hannover Medical School in Germany.
Merseburger presented these findings at the American Society of Clinical Oncology Genitourinary Cancers Symposium, held February 13-15, 2025, in San Francisco, California.
This transcript has been edited for clarity; captions were auto-generated.
Transcript
What was the rational for conducting the AVION study, a real-world analysis of avelumab and axitinib for renal cell carcinoma?
The rationale and the idea was we have the approval in a lot of countries for avelumab and axitinib for treating advanced and metastatic renal cell carcinoma, and we wanted to have a look at if this trial data, which was published and shown at several conferences, would stand also in real-world data in countries like Russia, Greece, and Germany that were the countries included in the AVION trial.
Were there any notable differences in outcomes or adverse events between the real-world study and what was seen in JAVELIN Renal 101?
Now, fortunately not, and this was really real life in European and even Russian sites that recruited the patients. Some of them haven't had any access to further subsequent treatment, which probably resulted also in this overall survival, similar to JAVELIN Renal 101.1
I think no, there's not a big difference, and the real-world data supports what we have found in the pivotal trial.
The observation period was 24 months. Is there a need for a longer follow-up period and what might it tell us or confirm?
Yes, we will do the follow-up. We will continue to do the follow-up and hope to report maybe at next year's ASCO GU 2026. Also, the publication plan is there. And once we have had more follow-up data, it's going to be published in a journal. We don't know where yet, but it's going to be definitely published.
Reference
Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103-1115. doi:10.1056/NEJMoa1816047
Understanding Primary and Secondary Nonadherence to Chronic Oral Medication
March 28th 2025Medication nonadherence to oral anticoagulants and oral anti–prostate cancer medication has been scrutinized through new research conducted among patients and health care providers and presented by the American Medical Group Association at its 2025 annual meeting, held March 26-29 in Grapevine, Texas.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More
Dermatologists Advocating for Inclusive Hair Loss Research and Treatment in the African Diaspora
March 26th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, advocates for increased funding and education to address hair loss disparities within the African diaspora, emphasizing the need for culturally sensitive treatment and research.
Read More
High Drug Costs, PBM Reform, and Access Challenges Take Center Stage at AMCP 2025
March 25th 2025As managed care pharmacy navigates rapid transformations in policies, high-cost drug strategies, and innovative therapies, the upcoming AMCP annual meeting will provide critical insights into legislative impacts, drug affordability, formulary design, and emerging treatment trends.
Read More